| Summary: | The PACIFIC trial uncovered a new era of immunotherapy in the multi-disciplinary treatment of unresectable locally advanced non-small cell lung cancer (LA-NSCLC), but also proposed a new question of how to further optimize radiotherapy and chemotherapy, in order to maximize synergistic effects with immunotherapy. The treatment progress of unresectable LA-NSCLC was reviewed in the context of immunotherapy. Updated data of the PACIFIC trial along with the research progress among special populations, especially for elderly patients, programmed death ligand-1 (PD-L1) expression negative and epidermal growth factor receptor (EGFR) gene mutant were summarized. Meanwhile, the optimal sequence of radiotherapy, chemotherapy and immunotherapy, the technical advancement and implementation of radiotherapy, including dose fractionation, target delineation and ray selection, were discussed, as well as its application prospect in the era of immunotherapy.
|
|---|